Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by westcoast1000on Mar 15, 2023 12:42pm
142 Views
Post# 35340194

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:ONCY Putting It's Best Foot Forward

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:ONCY Putting It's Best Foot ForwardI can readily see the viewpoints of Ionc and Fox. 

Many of us have a great deal tied up here.

But note the date: this piece came out in November, 2022. That was when the data first came out for the panc trial and before the Fast track designation.

ONCY does need to try and keep the retail price up as much as possible as part of keeping the ship afloat from November until the negotiations end somehow.

So while I would rather not have this kind of report be needed, it is part of getting the message out. Understanding clinical results is harder than almost any other investing information, and there is real complexity associated with those results. They need someone to tell the story. This piece came out around the time of the KOL seminar, which was also a more high brow version of getting the message out. 
<< Previous
Bullboard Posts
Next >>